NCT03179761View on ClinicalTrials.gov

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

February 15, 2022

Study Completion Date

October 1, 2024

Conditions
Hematopoietic Cell Transplantation
Interventions
BIOLOGICAL

Quadrivalent Inactivated Influenza Vaccine

Standard Dose Quadrivalent Influenza Vaccine given intramuscularly

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Trivalent Influenza Vaccine

High Dose Trivalent Influenza Vaccine given intramuscularly

Trial Locations (4)

35233

University of Alabama, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

60611

Northwestern University, Chicago

98109

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03179761 - High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients | Biotech Hunter | Biotech Hunter